Filing Flows › Aktis Oncology (AKTS) › Q2 2026 › vs Q2 2025
Aktis Oncology (AKTS) Q2 2026 vs Q2 2025 (year over year)
Aktis Oncology's revenue rose $1.8M (+111%) from $1.6M in Q2 2025 to $3.4M in Q2 2026.
Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%, net loss $24.1M, operating cash flow −$20.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.4M | $1.6M | $1.8M | +111% |
| Other income, net | $4.8M | $2.9M | $1.9M | +65% |
| Net loss | $24.1M | $18.1M | $6.1M | +34% |
| Costs & expenses | $32.3M | $22.6M | $9.7M | +43% |
| Operating costs | $32.3M | $22.6M | $9.7M | +43% |
| Research & development | $25.3M | $18.6M | $6.7M | +36% |
| General & admin | $7.0M | $3.9M | $3.1M | +78% |
| Operating cash sources | $24.7M | $18.2M | $6.4M | +35% |
| Depreciation & amortization | $879K | $552K | $327K | +59% |
| Share-based compensation | $3.2M | $1.5M | $1.7M | +112% |
| Cash used in operations | $20.6M | $16.2M | $4.4M | +27% |
| Net loss absorbed | $24.1M | $18.1M | $6.1M | +34% |
| Working capital & other | $544K | $175K | $369K | +211% |
Questions
How much did Aktis Oncology's revenue grow year over year in Q2 2026?
Aktis Oncology's revenue rose $1.8M (+111%) from $1.6M in Q2 2025 to $3.4M in Q2 2026.